(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Lincoln National Corporation stands third on our ...

Large private investment firm, Bain Capital, plans to sell its majority stake in an insurance broker and agency network based ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...